The Biorepository of this consortium provides the necessary infrastructure for all the projects to achieve their potential and expedite their findings.
The Biorepository is an integral component of the CRC since it processes and banks specimens that are needed for all projects. This Biorepository furnishes an accurate and complete characterization of each CLL specimen and allows for hypothesis-driven basic and clinical studies to be performed by the members of the consortium. This interactive information on each CLL sample allows CRC investigators and clinicians to better understand the biology of CLL and perform improved prognosis and clinical trials for this leukemia.
This biorepository performs all the studies with the patient’s informed consent that is approved by the Institutional Review Board (IRB) of each CRC site and maintained according to the guidelines established by the Health Insurance Probability and Accountability Act (HIPPA).